On the stock market since 2019, it operates in the world of health and science. It has 339 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $654K a year. A small number, but proof the product has real buyers.
There is $1.3B in the vault; even if every debt were paid off, $1.2B would remain.
A loss of $433.7M against $654K in annual sales. And on top of that, sales fell from the year before.
Over the last 12 months, executives reported 183 sells against just 55 buys. Not an alarm bell by itself, but a number worth watching.
The stock trades 22% above the average analyst price target.
On our five-subject report card, KRTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: KRTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.